Skip to content
AnalystLens

Merck 8-K Report, Financial Results (Apr 30, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed April 30, 2026
Period End
April 30, 2026
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Nov ’24Nov ’24

Summary

Summary of the 8-K filed April 30, 2026. Cited figures are marked; the original filing is the authoritative source.

Merck & Co. (MRK) reported first-quarter 2026 sales of $16.3 billiona, up 5% reported and 3% excluding foreign exchange, driven by Keytruda/Keytruda Qlex ($8.0 billion, up 12%), WINREVAIR ($525 million, up 88%), and Animal Health ($1.8 billion, up 13%).

However, GAAP and non-GAAP results were heavily depressed by a one-time $9.0 billionb charge ($3.62 per share) for the acquisition of Cidara Therapeutics, producing a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28, compared with GAAP EPS of $2.01 and non-GAAP EPS of $2.22 a year earlier. Excluding the Cidara charge, the underlying business trends are more meaningful: non-GAAP gross margin was 81.9% versus 82.2%, and continued growth in oncology, cardiometabolic, and animal health offset declines in Gardasil (down 19%, largely on lower China demand), Januvia/Janumet (down 28%), and Lagevrio (down 73%). Management narrowed and raised the midpoint of its full-year 2026 guidance, now calling for sales of $65.8 billion to $67.0 billion (prior $65.5 billion to $67.0 billion) and non-GAAP EPS of $5.04 to $5.16 (prior $5.00 to $5.15), both including the Cidara charge.

Importantly, the outlook excludes the pending acquisition of Terns Pharmaceuticals, which is expected to close in May 2026 and carry a one-time charge of approximately $5.8 billionc, or about $2.35 per share, plus an estimated $0.12 per share of further EPS drag over the remainder of 2026 from TERN-701 investment and financing costs. Investors will need to weigh this near-term earnings dilution against the strategic push to diversify the portfolio beyond Keytruda, which faces biosimilar and patent-cycle risks over time. Pipeline news was mixed.

Positive developments included FDA approval of IDVYNSO (an oral once-daily HIV regimen), approval of Keytruda for platinum-resistant ovarian cancer, and positive Phase 3 KEYNOTE-B15 results with a priority review (PDUFA August 17, 2026). Setbacks included several Phase 3 readouts that failed to reach statistical significance, notably LITESPARK-012 in renal cell carcinoma, KEYNOTE-975 in esophageal cancer, and KEYNOTE-866 in muscle-invasive bladder cancer. Upcoming catalysts include multiple PDUFA dates in June, August, and October 2026 and an Oncology Investor Event on June 1, 2026.

Key Highlights

  1. Q1 2026 sales of $16.3 billion grew 5% (3% ex-FX), led by Keytruda/Keytruda Qlex at $8.0 billion (up 12%) and WINREVAIR at $525 million (up 88%).
  2. GAAP and non-GAAP loss per share of $1.72 and $1.28, respectively, driven by a $3.62 per share ($9.0 billion) one-time charge for the Cidara Therapeutics acquisition.
  3. Non-GAAP gross margin of 81.9% versus 82.2% a year ago, with the decline primarily due to unfavorable FX.
  4. Full-year 2026 sales guidance narrowed and raised at the midpoint to $65.8–$67.0 billion; non-GAAP EPS guidance raised to $5.04–$5.16 from $5.00–$5.15.
  5. Guidance excludes the pending Terns Pharmaceuticals acquisition (expected close in May), which implies a ~$5.8 billion (~$2.35 per share) one-time charge plus ~$0.12 per share of additional 2026 EPS drag.
  6. Mixed pipeline: IDVYNSO HIV approval and positive KEYNOTE-B15 data offset failed Phase 3 readouts in RCC (LITESPARK-012), esophageal cancer (KEYNOTE-975), and bladder cancer (KEYNOTE-866).
  7. Declines in Gardasil (down 19%, largely China), Januvia/Janumet (down 28%), and Lagevrio (down 73%) continue to weigh on the legacy portfolio.

Frequently Asked Questions

  1. Why did Merck report a loss per share in Q1 2026 when it earned $2.01 per share a year earlier?

    The loss was driven by a one-time $9.0 billion charge ($3.62 per share) for the acquisition of Cidara Therapeutics, recorded in R&D expense because the transaction was treated as an asset acquisition. Excluding this charge, Merck would have posted positive earnings, although underlying non-GAAP results were still lower than the prior year due to higher interest expense, FX headwinds, and product declines.

  2. What is the impact of the pending Terns Pharmaceuticals acquisition on 2026 earnings?

    Merck expects a one-time charge of approximately $5.8 billion, or about $2.35 per share, when the Terns deal closes, which is expected in May 2026. Including operational investment in TERN-701 and financing costs, management also expects roughly $0.12 per share of additional EPS drag over the remainder of 2026. The current guidance does not reflect any of these effects.

  3. How is Merck's revenue growth being driven, and how dependent is it on Keytruda?

    Growth is concentrated in a few areas: Keytruda/Keytruda Qlex contributed about $8.0 billion, up 12%, but part of that growth reflected the timing of U.S. wholesaler purchases. WINREVAIR, Animal Health, Welireg, and Prevymis also grew strongly. Keytruda represents roughly half of total sales, so the company's ongoing diversification effort, including recent acquisitions and launches, is meant to reduce that long-term reliance.

  4. What were the notable pipeline setbacks and upcoming catalysts?

    Setbacks included Phase 3 trials that did not meet their primary endpoints: LITESPARK-012 (first-line RCC), KEYNOTE-975 (esophageal cancer), and KEYNOTE-866 (cisplatin-eligible MIBC, in an interim analysis). Positive catalysts include PDUFA dates for WELIREG combined with KEYTRUDA in adjuvant RCC on June 19, 2026, KEYTRUDA plus Padcev in MIBC on August 17, 2026, I-DXd in small cell lung cancer on October 10, 2026, and WELIREG plus Lenvima on October 4, 2026, along with an Oncology Investor Event on June 1, 2026.

  5. Did Merck change its full-year 2026 guidance, and what drove the change?

    Yes, modestly. Sales guidance was narrowed to $65.8–$67.0 billion from $65.5–$67.0 billion, with the midpoint raised, and non-GAAP EPS guidance was raised to $5.04–$5.16 from $5.00–$5.15. Management attributed part of the change to a positive FX impact of about 1% on sales and roughly $0.10 per share on EPS at mid-April exchange rates. Non-GAAP gross margin, tax rate, and share count guidance were unchanged.